AMRS [NASD]
Amyris, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own0.10% Shs Outstand312.90M Perf Week-2.12%
Market Cap538.25M Forward P/E- EPS next Y-0.32 Insider Trans8.07% Shs Float224.59M Perf Month-42.54%
Income-87.60M PEG- EPS next Q-0.38 Inst Own51.90% Short Float19.08% Perf Quarter-48.78%
Sales222.70M P/S2.42 EPS this Y50.80% Inst Trans11.26% Short Ratio7.32 Perf Half Y-67.65%
Book/sh-0.51 P/B- EPS next Y- ROA- Target Price14.33 Perf Year-82.90%
Cash/sh1.24 P/C1.87 EPS next 5Y- ROE- 52W Range1.47 - 17.42 Perf YTD-57.30%
Dividend- P/FCF- EPS past 5Y31.50% ROI-30.40% 52W High-86.74% Beta1.83
Dividend %- Quick Ratio1.50 Sales past 5Y38.50% Gross Margin19.00% 52W Low57.59% ATR0.41
Employees980 Current Ratio1.80 Sales Q/Q-67.40% Oper. Margin- RSI (14)39.14 Volatility14.59% 17.15%
OptionableYes Debt/Eq- EPS Q/Q64.50% Profit Margin- Rel Volume1.06 Prev Close2.42
ShortableYes LT Debt/Eq- EarningsMay 10 BMO Payout- Avg Volume5.85M Price2.31
Recom- SMA20-22.56% SMA50-39.51% SMA200-70.28% Volume6,206,189 Change-4.55%
Mar-02-22Resumed Cowen Outperform
Oct-15-21Resumed Cowen Outperform $19
Jun-01-21Initiated HSBC Securities Buy $20
Mar-03-21Reiterated H.C. Wainwright Buy $11 → $35
Feb-26-21Initiated ROTH Capital Buy $20
Jan-06-21Upgrade Cowen Market Perform → Outperform $9
Nov-25-20Initiated Jefferies Buy $3.35
Nov-25-20Initiated Cowen Market Perform $5
Dec-12-19Initiated Oppenheimer Outperform $8
Nov-14-18Reiterated B. Riley FBR Buy $10 → $8
Jan-25-18Initiated B. Riley FBR, Inc. Buy $8
May-28-14Resumed Stifel Hold
Feb-10-12Downgrade Deutsche Bank Buy → Hold $20 → $9
Nov-02-11Downgrade Robert W. Baird Outperform → Neutral $25 → $16
Jan-28-11Downgrade Stifel Nicolaus Buy → Hold
Nov-08-10Initiated Stifel Nicolaus Buy $22
May-22-22 06:11AM  
May-12-22 07:48AM  
May-10-22 08:30PM  
09:25AM  
08:00AM  
May-03-22 08:00AM  
May-02-22 07:47AM  
Apr-28-22 06:15PM  
Apr-14-22 08:00AM  
Apr-11-22 08:00AM  
Apr-08-22 06:15PM  
Apr-06-22 11:45AM  
Mar-29-22 08:00AM  
Mar-24-22 06:07AM  
Mar-17-22 08:00AM  
Mar-15-22 06:15PM  
Mar-11-22 08:00AM  
Mar-04-22 07:05AM  
Mar-01-22 08:00AM  
Feb-28-22 08:00AM  
07:07AM  
Feb-27-22 10:52AM  
Feb-22-22 08:00AM  
Feb-14-22 06:15PM  
Feb-09-22 08:00AM  
Feb-08-22 06:15PM  
Feb-03-22 05:38PM  
Feb-02-22 09:38AM  
Feb-01-22 06:15PM  
Jan-27-22 08:00AM  
Jan-26-22 06:15PM  
Jan-24-22 08:00AM  
Jan-18-22 09:38AM  
Jan-14-22 06:15PM  
04:51PM  
Jan-13-22 10:56AM  
Jan-07-22 06:15PM  
Jan-05-22 08:00AM  
Jan-03-22 12:50PM  
08:00AM  
Dec-23-21 07:00AM  
Dec-20-21 08:35AM  
06:00AM  
Dec-18-21 05:43AM  
Dec-15-21 01:38AM  
Dec-12-21 07:00AM  
Dec-10-21 05:15PM  
Dec-08-21 12:57PM  
Nov-30-21 08:00AM  
Nov-23-21 04:05PM  
10:41AM  
Nov-18-21 09:12AM  
Nov-15-21 05:31PM  
Nov-11-21 07:15PM  
Nov-10-21 08:00AM  
Nov-09-21 02:50PM  
02:30AM  
Nov-08-21 06:05PM  
05:14PM  
04:35PM  
04:11PM  
10:15AM  
08:00AM  
Oct-28-21 03:06PM  
08:00AM  
Oct-27-21 06:17AM  
Oct-25-21 10:08AM  
Oct-20-21 06:17AM  
Oct-13-21 05:45AM  
Oct-12-21 05:43AM  
Oct-05-21 08:00AM  
Oct-01-21 08:00AM  
Sep-22-21 08:00AM  
Sep-13-21 06:51AM  
Sep-08-21 08:00AM  
Sep-07-21 08:00AM  
Aug-26-21 08:30AM  
Aug-24-21 08:30AM  
08:00AM  
Aug-23-21 08:00AM  
Aug-20-21 03:51PM  
10:12AM  
08:00AM  
Aug-19-21 08:00AM  
Aug-16-21 08:00AM  
04:15AM  
Aug-13-21 06:51PM  
05:09PM  
Aug-09-21 06:23AM  
Aug-05-21 07:30PM  
10:05AM  
08:00AM  
Aug-03-21 08:00AM  
06:16AM  
Jul-29-21 03:05PM  
Jul-22-21 08:00AM  
Jul-21-21 08:00AM  
Jul-16-21 10:38PM  
Jul-13-21 08:00AM  
Jul-11-21 08:43AM  
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCCANN JAMES FDirectorDec 06Buy5.7117,40099,35429,831Dec 08 07:51 PM
DOERR L JOHNDirectorSep 09Option Exercise2.873,778,23010,843,52073,935,024Sep 13 07:01 PM
ALVAREZ EDUARDOCHIEF OPERATING OFFICERSep 02Sale14.8617,605261,610371,335Sep 03 09:56 PM
KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSep 02Sale14.863,48351,757155,772Sep 03 09:55 PM
Kieftenbeld HermanusCHIEF FINANCIAL OFFICERSep 02Sale14.8624,380362,287281,560Sep 03 09:54 PM
Hughes AnthonyCHIEF ACCOUNTING OFFICERSep 02Sale14.861,16217,26782,917Sep 03 09:54 PM
Melo JohnPresident and CEOJul 07Sale15.5395,1151,477,012548,277Jul 09 05:44 PM